Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

SIMPLE SUMMARY: Immune checkpoint blockade (ICB) with antibodies targeting CTLA-4 (Cytotoxic Lymphocyte Antigen 4) and/or programmed death-1 protein (PD-1)/programmed death ligand-1 (PD-L1) has significantly modified the therapeutic landscape of a broad range of human tumor types, including advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Grottoli, Melania, Carrega, Paolo, Zullo, Lodovica, Dellepiane, Chiara, Rossi, Giovanni, Parisi, Francesca, Barletta, Giulia, Zinoli, Linda, Coco, Simona, Alama, Angela, Marconi, Silvia, Parodi, Monica, Orecchia, Paola, Bassi, Sara, Vitale, Massimo, Mingari, Maria Cristina, Pfeffer, Ulrich, Genova, Carlo, Pietra, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599824/
https://www.ncbi.nlm.nih.gov/pubmed/36291830
http://dx.doi.org/10.3390/cancers14205046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599824/
https://www.ncbi.nlm.nih.gov/pubmed/36291830
http://dx.doi.org/10.3390/cancers14205046

Ejemplares similares